Overview

Overview

Investor Relations

Last News

More News >

4.1.12
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007
5.3.11
Rutgers Offers Hope in New Treatment for Spinal Cord Injuries
18.3.11
In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months
15.7.10
Nitto Denko and Quark Pharmaceuticals to Enter into Collaboration to Develop a Novel siRNA Anti-fibrotic Drug
28.6.10
Quark Pharmaceutical’s QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model

Overview

Please contact us directly for any inquire related to investor relations.